Study summary · research use only
Orforglipron
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This brief reference entry describes orforglipron, an orally available glucagon-like peptide-1 (GLP-1) receptor agonist approved as a weight-loss agent. It reports that rates of serum aminotransferase elevation during orforglipron therapy were no higher than with placebo, and that orforglipron has not been linked to reported instances of clinically apparent liver injury with symptoms or jaundice.
Abstract
Orforglipron is an orally available, glucagon-like peptide-1 (GLP-1) receptor agonist that is approved as a weight loss agent. Rates of serum aminotransferase elevations during orforglipron therapy are no higher than with placebo and it has not been linked to instances of clinically apparent liver injury with symptoms or jaundice.
pepmg summarizes the peer-reviewed literature and links to every source. It sells nothing and ships nothing. Where an FDA label, a peer-reviewed study or a clinical-trial registry entry (labeled trial registry, not peer-reviewed) has published a dose, pepmg reports it with the source named; it gives no personalized recommendations and no administration technique. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.